FDA Issues Approvable Letter for Forest Lab's Nebivolol

Forest Laboratories Inc. and licensing partner Mylan Inc. said Mylan has received an approvable letter from the U.S. Food and Drug Administration in response to its new drug application (NDA) for nebivolol under the proposed brand name Bystolic, a novel beta-blocker under review for the treatment of hypertension.
CNN Money